|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||383.92 g·mol−1|
|3D model (JSmol)|
4'Cl-CUMYL-PINACA (also known as SGT-157) is an indazole-3-carboxamide based synthetic cannabinoid compound, first disclosed in a 2014 patent. It has been sold as a designer drug, first reported in 2020 alongside two similar compounds 4'F-CUMYL-5F-PICA (SGT-64) and 4'F-CUMYL-5F-PINACA (SGT-65), and the metabolism of these compounds has been studied to assist with their identification in forensic casework.
- WO 2014167530, Bowden MJ, Williamson JP, "Cannabinoid compounds", published 16 October 2014.
- Zangani C, Schifano F, Napoletano F, Arillotta D, Gilgar L, Guirguis A, et al. (2020). "The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online". Current Neuropharmacology. 18 (10): 966–1051. doi:10.2174/1570159X18666200302125146. PMC 7709145. PMID 32116194.
- Stalberga D, Ingvarsson S, Bessa G, Maas L, Vikingsson S, Persson M, et al. (December 2022). "Metabolism studies of 4'Cl-CUMYL-PINACA, 4'F-CUMYL-5F-PINACA and 4'F-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis" (PDF). Basic & Clinical Pharmacology & Toxicology. 132 (3): 263–280. doi:10.1111/bcpt.13829. PMID 36544361. S2CID 255039508.